Skip to main content
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Publisher: Bentham Science Publishers

More about this publication?
Volume 18, Number 28, 2011

Articles

Monocyclic β-Lactams: New Structures for New Biological Activities
pp. 4265-4283(19)
Authors: Galletti, P.; Giacomini, D.

Favourites:
ADD

New Therapeutic Strategy for Mood Disorders
pp. 4284-4298(15)
Authors: Crupi, R.; Marino, A.; Cuzzocrea, S.

Favourites:
ADD

Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
pp. 4299-4320(22)
Authors: Mohamed, T.; P.N. Rao, P.

Favourites:
ADD

Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
pp. 4321-4334(14)
Authors: D. Rodriguez, F.; Covenas, R.

Favourites:
ADD

Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
pp. 4335-4343(9)
Authors: Zhang, Z.; Yan, J.; Chang, Y.; ShiDu Yan, S.; Shi, H.

Favourites:
ADD

Open Access Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
pp. 4344-4358(15)
Authors: M. Waszkielewicz, A.; Gunia, A.; Sloczynska, K.; Marona, H.

Favourites:
ADD

Promoting Adult Hippocampal Neurogenesis: A Novel Strategy for Antidepressant Drug Screening
pp. 4359-4367(9)
Authors: Yan, H.-C.; Cao, X.; Gao, T.-M.; Zhu, X.-H.

Favourites:
ADD

Current Inhibitors of Checkpoint Kinase 2
pp. 4368-4374(7)
Authors: N.T. Nguyen, T.; J. Tepe, J.

Favourites:
ADD
Favourites:
ADD

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
pp. 4389-4409(21)
Authors: Sheng, Chunquan; Miao, Zhenyuan; Zhang, Wannian

Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content